161 related articles for article (PubMed ID: 38013350)
1. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria.
Echefu SN; Udosen JE; Akwiwu EC; Akpotuzor JO; Obeagu EI
Medicine (Baltimore); 2023 Nov; 102(47):e35910. PubMed ID: 38013350
[TBL] [Abstract][Full Text] [Related]
2. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
Walmsley SL; Antela A; Clumeck N; Duiculescu D; Eberhard A; Gutiérrez F; Hocqueloux L; Maggiolo F; Sandkovsky U; Granier C; Pappa K; Wynne B; Min S; Nichols G;
N Engl J Med; 2013 Nov; 369(19):1807-18. PubMed ID: 24195548
[TBL] [Abstract][Full Text] [Related]
3. Durability of first-line antiretroviral regimens in the era of integrase inhibitors: a cohort of HIV-positive individuals in Spain, 2014-2015.
Jarrin I; Suarez-Garcia I; Moreno C; Tasias M; Del Romero J; Palacios R; Peraire J; Gorgolas M; Moreno S;
Antivir Ther; 2019; 24(3):167-175. PubMed ID: 30747107
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.
Peng S; Tafazzoli A; Dorman E; Rosenblatt L; Villasis-Keever A; Sorensen S
J Med Econ; 2015; 18(10):763-76. PubMed ID: 25934146
[TBL] [Abstract][Full Text] [Related]
5. Effects of Highly Active Antiretroviral Therapy on Albuminuria in HIVinfected Persons.
Adedeji TA; Adebisi SA; Adedeji NO
Infect Disord Drug Targets; 2020; 20(3):374-384. PubMed ID: 31389318
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in the UK, based on the AIDS Clinical Trials Group 5202 clinical trial.
Wilkins E; Fisher M; Brogan AJ; Talbird SE; La EM
HIV Med; 2016 Aug; 17(7):505-15. PubMed ID: 26663715
[TBL] [Abstract][Full Text] [Related]
7. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.
McComsey GA; Kitch D; Daar ES; Tierney C; Jahed NC; Tebas P; Myers L; Melbourne K; Ha B; Sax PE
J Infect Dis; 2011 Jun; 203(12):1791-801. PubMed ID: 21606537
[TBL] [Abstract][Full Text] [Related]
8. Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens.
Norwood J; Turner M; Bofill C; Rebeiro P; Shepherd B; Bebawy S; Hulgan T; Raffanti S; Haas DW; Sterling TR; Koethe JR
J Acquir Immune Defic Syndr; 2017 Dec; 76(5):527-531. PubMed ID: 28825943
[TBL] [Abstract][Full Text] [Related]
9. Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain.
Moreno Guillen S; Losa García JE; Berenguer Berenguer J; Martínez Sesmero JM; Cenoz Gomis S; Graefenhain R; Lopez Sanchez-Cambronero D; Parrondo Garcia FJ
Farm Hosp; 2017 Sep; 41(5):601-610. PubMed ID: 28847249
[TBL] [Abstract][Full Text] [Related]
10. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
Venter WDF; Moorhouse M; Sokhela S; Fairlie L; Mashabane N; Masenya M; Serenata C; Akpomiemie G; Qavi A; Chandiwana N; Norris S; Chersich M; Clayden P; Abrams E; Arulappan N; Vos A; McCann K; Simmons B; Hill A
N Engl J Med; 2019 Aug; 381(9):803-815. PubMed ID: 31339677
[TBL] [Abstract][Full Text] [Related]
11. Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection.
Deng L; Li C; Chen P; Luo X; Zheng X; Zhou L; Zhou Y; Xia J; Hong Z
BMC Infect Dis; 2022 Jan; 22(1):17. PubMed ID: 34983415
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 genital shedding in HIV-infected patients randomized to second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir.
Bunupuradah T; Bowonwattanuwong C; Jirajariyavej S; Munsakul W; Klinbuayaem V; Sophonphan J; Mahanontharit A; Hirschel B; Ruxrungtham K; Ananworanich J;
Antivir Ther; 2014; 19(6):579-86. PubMed ID: 24464590
[TBL] [Abstract][Full Text] [Related]
13. Evolution of blood lipids and risk factors of dyslipidemia among people living with human immunodeficiency virus who had received first-line antiretroviral regimens for 3 years in Shenzhen.
Sun LQ; Liu JY; He Y; Zhou Y; Xu LM; Zhang LK; Zhao F; Liu XN; Song Y; Cao TZ; Tian YM; Rao M; Wang H
Chin Med J (Engl); 2020 Dec; 133(23):2808-2815. PubMed ID: 33273329
[TBL] [Abstract][Full Text] [Related]
14. Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.
Raffi F; Rachlis A; Brinson C; Arasteh K; Górgolas M; Brennan C; Pappa K; Almond S; Granier C; Nichols WG; Cuffe RL; Eron J; Walmsley S
AIDS; 2015 Jan; 29(2):167-74. PubMed ID: 25387312
[TBL] [Abstract][Full Text] [Related]
15. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.
Sax PE; Tierney C; Collier AC; Daar ES; Mollan K; Budhathoki C; Godfrey C; Jahed NC; Myers L; Katzenstein D; Farajallah A; Rooney JF; Ha B; Woodward WC; Feinberg J; Tashima K; Murphy RL; Fischl MA;
J Infect Dis; 2011 Oct; 204(8):1191-201. PubMed ID: 21917892
[TBL] [Abstract][Full Text] [Related]
16. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
Hill A; Sawyer W
HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression.
Huang WC; Huang CK; Huang SH; Lin SW; Ou ST; Chen YT; Chen YW; Chang SY; Liu WC; Sun HY; Hung CC
J Microbiol Immunol Infect; 2021 Oct; 54(5):944-951. PubMed ID: 32675042
[TBL] [Abstract][Full Text] [Related]
18. Treatment Outcomes of Dolutegravir- Versus Efavirenz-Based Highly Active Antiretroviral Therapy Regimens Among Treatment-Naive People Living With HIV.
Mahale PR; Patel BS; Kasmani N
Cureus; 2023 Jun; 15(6):e40139. PubMed ID: 37435267
[TBL] [Abstract][Full Text] [Related]
19. Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.
Lackey P; Mills A; Carpio F; Hsu R; DeJesus E; Pierone G; Henegar C; Fusco J; Fusco G; Wohlfeiler M
Clin Drug Investig; 2017 Jan; 37(1):51-60. PubMed ID: 27587070
[TBL] [Abstract][Full Text] [Related]
20. Improving access to antiretrovirals in China: economic analyses of dolutegravir in HIV-1 patients.
Punekar YS; Guo N; Tremblay G; Piercy J; Holbrook T; Young B
Cost Eff Resour Alloc; 2019; 17():26. PubMed ID: 31827410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
